Integrative Krebstherapie: facettenreich, innovativ und fachübergreifend denken – im Netzwerk sind wir stark

Dr. med. Matthias Kraft
Grütstrasse 55
8802 Kilchberg | Schweiz
kraftmatthias@web.de

Dr. med. Kurt Mosetter
Obere Laube 44
78462 Konstanz | Deutschland
kurt@mosetter.de
www.myoreflex.de

Univ. Prof. Dr. rer. nat. Florian Überall
Franz-Stockmayer-Straße 30A
6419 Telfs | Österreich
info@florianueberall.at
WWW.florianueberall.at

Dr. Olaf Katzler
Schäferkampsallee 34
20357 Hamburg | Deutschland
katzler@mammazentrum-hamburg.de
www.mammazentrum-hamburg.de

Literatur

[1] *Islami F, Marlow EC et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, 2019 CA Cancer J Clin. 2024 74:405-432*

[2] *Robert Koch-Institut / Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. Dr. Peter Kaatsch, Dr. Claudia Spix, Prof. Dr. Alexander Katalinic, Dr. Stefan Hentschel, Dr. Sabine Luttmann, Christa Stegmaier: Krebs in Deutschland 2011/2012*

[3] *Calle E. E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nature reviews. Cancer 2004 4:579–591*

[4] *Romaguera D., Vergnaud A.C. et al. Is concordance with World Cancer Research Fund/American Institute for Cancer Research guidelines for cancer prevention related to subsequent risk of cancer? Results from the EPIC study. The American journal of clinical nutrition, 2012 96:150–163.*

[5] *WHO Consultation on Obesity (1999: Geneva, Switzerland) & World Health Organization. 2000 Obesity: preventing and managing the global epidemic: report of a WHO consultation. World Health Organization. https://iris.who.int/handle/10665/42330*

[6] *Jährliche Krebsneuerkrankungen und Todesfälle aufgrund von Krebs nach Geschlecht 2022. Veröffentlicht von Rainer Radtke, 06.11.2024. https://de.statista.com*

[7] *Islami F., Goding Sauer A et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA: a cancer journal for clinicians, 2018 68:31–54.*

[8] *Yang L., Li A. et al. Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy. Signal transduction and targeted therapy 2023 8:35*

[9] *Kong C., Liang, L. et al. Integrated metagenomic and metabolomic analysis reveals distinct gut-microbiome-derived phenotypes in early-onset colorectal cancer. Gut 2023 72:1129–1142*

[10] *Waghela B. N., Vaidya F. U. et al.. AGE-RAGE synergy influences programmed cell death signaling to promote cancer. Molecular and cellular biochemistry 2021 476(2): 585–598.*

[11] *Belachew E. B., Sewasew D. T. Molecular Mechanisms of Endocrine Resistance in Estrogen-Positive Breast Cancer. Frontiers in endocrinology 2021 12:599586.*

[12] *Scalia P., Giordano A. et al. Isoform- and Paralog-Switching in IR-Signaling: When Diabetes Opens the Gates to Cancer. Biomolecules 2020 10:1617.*

[13] *Sohrab S. S., Raj R. et al. Chronic Inflammation's Transformation to Cancer: A Nanotherapeutic Paradigm. Molecules (Basel, Switzerland) 2023 28:4413*

[14] *Liu Y., Sun Y. et al. An Overview: The Diversified Role of Mitochondria in Cancer Metabolism. International journal of biological sciences 2023 19(3):897–915*

[15] *Jelic M. D., Mandic A. D. et al. Oxidative stress and its role in cancer. Journal of cancer research and therapeutics 2021 17(1):22–28*

[16] *Dai S., Mo, Y. Chronic Stress Promotes Cancer Development. Frontiers in oncology 2020 10:1492*

[17] *Cordova M. J., Riba M. B., Spiegel, D. Post-traumatic stress disorder and cancer. The lancet. Psychiatry 2017 4(4):330–338*

[18] *Rusin, A., Seymour, C. et al. Commonalities in the Features of Cancer and Chronic Fatigue Syndrome (CFS): Evidence for Stress-Induced Phenotype Instability?. International journal of molecular sciences 2022 23(2):691*

[19] *Shang, Q., Yu X. et al. Polysaccharides regulate Th1/Th2 balance: A new strategy for tumor immunotherapy. Biomedicine & pharmacotherapy 2024 170:115976*

[20] Lee, N. W. et al. Air-polluted environmental heavy metal exposure increase lung cancer incidence and mortality: A population-based longitudinal cohort study. The Science of the total environment 2022 810:152186
[21] Kerr J., Anderson C., Lippman S. M. Physical activity, sedentary behaviour, diet, and cancer: an update and emerging new evidence. The Lancet. Oncology 2017 18(8):e457–e471
[22] Wei L., Wu Z., Chen Y. Q. Multi-targeted therapy of cancer by omega-3 fatty acids-an update. Cancer letters 2022 526:193–204
[23] Vega O. M., Abkenari S. et al. Omega-3 Polyunsaturated Fatty Acids and Lung Cancer: nutrition or Pharmacology? Nutrition and cancer 2021 73(4):541–561
[24] Jiang B., Zhang J. et al. Filamentous GLS1 promotes ROS-induced apoptosis upon glutamine deprivation via insufficient asparagine synthesis. Molecular cell 2022 82(10):1821–1835.e.
[25] Sheeley M. P., Andolino, C. et al. Vitamin D regulation of energy metabolism in cancer. British journal of pharmacology 2022 179(12):2890–2905
[26] Yang C. S., Luo P. et al.. Vitamin E and cancer prevention: Studies with different forms of tocopherols and tocotrienols. Molecular carcinogenesis 2020 59(4):365–389
[27] Schöttker B., Holleczek B. et al. Strong associations of serum selenoprotein P with all-cause mortality and mortality due to cancer, cardiovascular, respiratory and gastrointestinal diseases in older German adults. European journal of epidemiology 2024 39(2):121–136
[28] Peng F., Lu J. et al. Oncogenic fatty acid oxidation senses circadian disruption in sleep-deficiency-enhanced tumorigenesis. Cell metabolism 2024 36(7):1598–1618.e11
[29] Reiter R. J., De Almeida Chuffa L. G. et al. Melatonin and vitamin D as potential synergistic adjuvants for cancer therapy (Review). International journal of oncology 2024 65(6):114
[30] Wong-Rolle A., Wei H. K. et al. Unexpected guests in the tumor microenvironment: microbiome in cancer. Protein & cell 2021 12(5):426–435
[31] Seyfried T. N., Flores R. E. et al. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis 2014 35(3):515–527
[32] Pavlova N. N., Zhu J., Thompson C. B. The hallmarks of cancer metabolism: Still emerging. Cell metabolism 2022 34(3):355–377
[33] Zhang A. M. Y., Wellberg E. A. et al. Hyperinsulinemia in Obesity, Inflammation, and Cancer. Diabetes & metabolism journal 2021 45(3):285–311
[34] Muthyalaiah Y. S., Jonnalagadda B. et al.. Impact of Advanced Glycation End products (AGEs) and its receptor (RAGE) on cancer metabolic signaling pathways and its progression. Glycoconjugate journal 2021 38(6):717–734
[35] Ortmayr K., Dubuis S., Zampieri M. Metabolic profiling of cancer cells reveals genome-wide crosstalk between transcriptional regulators and metabolism. Nature communications 2019 10(1):1841
[36] Sharma A. K., Sharma V. R. et al. Advanced Glycation End Products (AGEs), Glutathione and Breast Cancer: Factors, Mechanism and Therapeutic Interventions. Current drug metabolism 2019 20(1):65–71
[37] Pan D., Guo J. et al. Association of the controlling nutritional status score with all-cause mortality and cancer mortality risk in patients with type 2 diabetes: NHANES 1999-2018. Diabetology & metabolic syndrome 2023 15(1):175
[38] Silbernagel G., Grammer T. B. et al. Glycated hemoglobin predicts all-cause, cardiovascular, and cancer mortality in people without a history of diabetes undergoing coronary angiography. Diabetes care 2011 34(6):1355–1361.
[39] Peila R., Roha T. E. Diabetes, Glycated Hemoglobin, and Risk of Cancer in the UK Biobank Study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2020 29(6):1107–1119
[40] Hart G. W. Nutrient regulation of signaling and transcription. The Journal of biological chemistry 2019 294(7):2211–2231
[41] Krisanits B. A., Woods P. et al. Non-enzymatic glycoxidation linked with nutrition enhances the tumorigenic capacity of prostate cancer epithelia through AGE mediated activation of RAGE in cancer associated fibroblasts. Translational oncology 2022 17:101350
[42] Scott E., Hodgson K. et al. Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth. Oncogene 2023 42(12):926–937
[43] Stanczak M. A., Rodrigues Mantuano N. et al. Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. Science translational medicine 2022 14(669):eabj1270
[44] Goyette M. A., Stevens L. E. et al. Cancer-stromal cell interactions in breast cancer brain metastases induce glycocalyx-mediated resistance to HER2-targeting therapies. Proceedings of the National Academy of Sciences of the United States of America 2024 121(20):e2322688121.
[45] Stewart N., Daly J. et al. The glycoimmune checkpoint receptor Siglec-7 interacts with T-cell ligands and regulates T-cell activation. The Journal of biological chemistry 2024 300(2):105579
[46] White J. Sucrose, HFCS, and Fructose: History, Manufacture, Composition, Applications, and Production 2014 pp. 13–33. Humana Press, New York, NY.
[47] Jung S, Bae H et al. Dietary fructose and fructose-induced pathologies. Annu Rev Nutr 2022 42:45–66
[48] Bode J, Empie M., Brenner K. Evolution of high fructose corn syrup within the sweeteners industry. In Fructose, High Fructose Corn Syrup, Sucrose and Health (JM Rippe, ed.), 2014 pp. 137–148. Springer, New York, NY.
[49] Parker K, Salas M & Nwosu V High fructose corn syrup: production, uses and public health concerns. Biotechnol Mol Biol Rev (2011) 5, 71–78

[50] Elliott SS, Keim NL et al. Fructose, weight gain, and the insulin resistance syndrome. Am J Clin Nutr. (2002) 76:911–22.
[51] Bray GA, Nielsen SJ, Popkin BM. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr. 2004 79:537–43
[52] Lustig RH, Schmidt LA, Brindis CD. The toxic truth about sugar. Nature. 2012 482:27–9.
[53] Ting KKY. Fructose overconsumption-induced reprogramming of microglia metabolism and function. Front Immunol 2024 15:1375453
[54] Goodman BE Insights into digestion and absorption of major nutrients in humans. Adv Physiol Educ 2010 34:44–53
[55] Holmes R. Carbohydrate digestion and absorption. J Clin Pathol 1971 s3-5:10–13
[56] Koepsell H. Glucose transporters in the small intestine in health and disease. Pflugers Arch 2020 472:1207–1248
[57] Chen L, Tuo B et al. Regulation of intestinal glucose absorption by ion channels and transporters. Nutrients 2016 8:43.
[58] Wright EM, Loo DDF, Hirayama BA Biology of human sodium glucose transporters. Physiol Rev 2011 91:733–794.
[59] Hediger MA, Rhoads DB Molecular physiology of sodium-glucose cotransporters. Physiol Rev 1994 74:993–1026
[60] Kellett GL, Brot-Laroche E et al. Sugar absorption in the intestine: the role of GLUT2. Annu Rev Nutr 2008 28:35–54
[61] Mueckler M, Thorens B The SLC2 (GLUT) family of membrane transporters. Mol Asp Med 2013 34:121–138
[62] Uldry M, Ibberson M et al. GLUT2 is a high affinity glucosamine transporter. FEBS Lett 2002 524:199–203
[63] Kellett GL, Brot-Laroche E Apical GLUT2: a major pathway of intestinal sugar absorption. Diabetes 2005 54:3056–3062
[64] Kellett GL The facilitated component of intestinal glucose absorption. J Physiol 2001 531:585–595
[65] Burant CF, Takeda J et al. Fructose transporter in human spermatozoa and small intestine is GLUT5. J Biol Chem 1992 267:14523–14526
[66] Kane S, Seatter MJ et al. Functional studies of human GLUT5: effect of pH on substrate selection and an analysis of substrate interactions. Biochem Biophys Res Commun 1997 238:503–505
[67] Blakemore SJ, Aledo JC et al. The GLUT5 hexose transporter is also localized to the basolateral membrane of the human jejunum. Biochem J 1995 309:7–12
[68] Alam YH, Kim R, Jang C Metabolism and health impacts of dietary sugars. J Lipid Atheroscler 2022 11:20–38
[69] Dashty M A quick look at biochemistry: carbohydrate metabolism. Clin
[Biochem 2013 46:1339–1352
[70] Frey PA The Leloir pathway: a mechanistic imperative for three enzymes to change the stereochemical configuration of a single carbon in galactose. FASEB J 1996 10:461–470
[71] Heinz F, Lamprecht W, Kirsch J Enzymes of fructose metabolism in human liver. J Clin Invest 1968 47:1826–1832
[72] Tappy L., Lê K-A. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev 2010 90:23–46
[73] Lim JS, Mietus-Snyder M. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 2010 7: 251–264
[74] van den Berghe G, Bronfman M et al. The mechanism of adenosine triphosphate depletion in the liver after a load of fructose. A kinetic study of liver adenylate deaminase. Biochem J 1977 162:601–609
[75] Johnson RJ, Nakagawa T. et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes 2013 62:3307–3315
[76] Lanaspa MA, Sanchez-Lozada LG et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J Biol Chem 2012 287:40732–40744
[77] Zhao S, Jang C et al. Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. Nature 2020 579:586–591
[78] Bizeau ME, Pagliassotti MJ Hepatic adaptations to sucrose and fructose. Metabolism 2005 54:1189–1201
[79] Jang C, Hui S et al. The small intestine converts dietary fructose into glucose and organic acids. Cell Metab 2018 27:351–361.e3
[80] Rajas F, Bruni N et al. The glucose-6 phosphatase gene is expressed in human and rat small intestine: regulation of expression in fasted and diabetic rats. Gastroenterology 1999 117:132–139
[81] Ter Horst KW, Serlie MJ. Fructose consumption, lipogenesis, and non-alcoholic fatty liver disease. Nutrients 2017 8:43
[82] Jang C, Wada S et al The small intestine shields the liver from fructose-induced steatosis. Nat Metab 2020 2:586–593
[83] Zhang C, Li L et al. Recent advances in fructose intake and risk of hyperuricemia. Biomed Pharmacother 2020 131:10795
[84] Warburg O. The metabolism of carcinoma cells1. J Cancer Res. 1925 9:148–63
[85] Warburg O, Wind F, Negelein E. Über den Stoffwechsel von Tumoren im Körper. Klinische Wochenschrift 1926 5:829–32
[86] Nam M, Xia W et al. Glucose limitation protects cancer cells from apoptosis induced by pyrimidine restriction and replication inhibition. Nat Metab 2024 16:2338-2353
[87] Warburg O. On the origin of cancer cells. Science 1956 123:309–14
[88] Vander Heiden MG, Cantley LC et al. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009 324:1029-33
[89] Gonzalez JT, Betts JA. Dietary Fructose Metabolism by Splanchnic Organs: Size Matters. Cell Metab 2018 27:483-485
[90] Bian Z, Zhang J. et al. LncRNA-FEZF1-AS1 promotes tumor proliferation and metastasis in colorectal cancer by regulating PKM2 signaling. Clin Cancer Res. 2018 24:4808–19.
[91] Kuo CC, Ling HH et al. Metastatic colorectal cancer rewrites metabolic program through a glut3-YAP-dependent signaling circuit. Theranostics 2019 9:2526–40

[92] Shen C, Xuan B et al. m6A-dependent glycolysis enhances colorectal cancer progression. Mol Cancer 2020 19:72
[93] Ji Y, Yang C et al. Adenylate kinase hCINAP determines self-renewal of colorectal cancer stem cells by facilitating LDHA phosphorylation. Nat Commun. 2017 8:15308
[94] Shen Z, Li Z et al. GLUT5-KHK axis-mediated fructose metabolism drives proliferation and chemotherapy resistance of colorectal cancer. Cancer Lett. 2022 534:215617.
[95] Włodarczyk J, Włodarczyk M et al. Blockade of fructose transporter protein GLUT5 inhibits proliferation of colon cancer cells: proof of concept for a new class of anti-tumor therapeutics. Pharmacol Rep. 2021 73:939–45
[96] Pan R, Liu J et al. Causal links of human serum metabolites on the risk of prostate cancer: insights from genome-wide Mendelian randomization, single-cell RNA sequencing, and metabolic pathway analysis. Front. Endocrinol. 2024 15:1443330
[97] Chen WL, Jin X et al. GLUT5-mediated fructose utilization drives lung cancer growth by stimulating fatty acid synthesis and AMPK/mTORC1 signaling. JCI Insight. 2020 5
[98] Weng Y, Fan X et al. SLC2A5 promotes lung adenocarcinoma cell growth and metastasis by enhancing fructose utilization. Cell Death Discovery 2018 4:38
[99] Zhang Y, Yu X et al. Dietary fructose-mediated adipocyte metabolism drives antitumor CD8(+) T cell responses. Cell Metab. 2023 35:2107–18.e6.
[100] Jiang Y, Pan Y et al. Asucrose-enriched diet promotes tumorigenesis in mammary gland in part through the 12-lipoxygenase pathway. Cancer Res. 2016 76:24–9
[101] Zamora-Leon SP, Golde DW et al. Expression of the fructose transporter GLUT5 in human breast cancer. Proc Natl Acad Sci U.S.A. 1996 93:1847–52.
[102] Fan X, Liu H et al. Increased utilization of fructose has a positive effect on the development of breast cancer. PeerJ. 2017 5:e3804.
[103] Chan KK, Chan JYW et al. Inhibition of cell proliferation in human breast tumor cells by antisense oligonucleotides against facilitative glucose transporter 5. J Cell Biochem. 2004 93:1134–42
[104] Monzavi-Karbassi B, Hine RJ et al. Fructose as a carbon source induces an aggressive phenotype in MDA-MB-468 breast tumor cells. Int J Oncol. 2010 37:615–22
[105] Kim J, Kang J et al. Ketohexokinase-A acts as a nuclear protein kinase that mediates fructose-induced metastasis in breast cancer. Nat Commun. 2020 11:5436
[106] Chen W-L, Wang Y-Y et al. Enhanced fructose utilization mediated by SLC2A5 is a unique metabolic feature of acute myeloid leukemia with therapeutic potential. Cancer Cell. 2016 30:779–91
[107] Jeong S, Savino AM et al. High fructose drives the serine synthesis pathway in acute myeloid leukemic cells. Cell Metab. 2021 33:145–59.e6.
[108] Carreño DV, Corro NB et al. Dietary fructose promotes prostate cancer growth. Cancer Res. 2021 81:2824–32
[109] Liu H, Huang D et al. Fructose induces transketolase flux to promote pancreatic cancer growth. Cancer Res. 2010 70:6368–76
[110] Su C, Li H, Gao W. GLUT5 increases fructose utilization and promotes tumor progression in glioma. Biochem Biophys Res Commun. 2018 500:462–9.
[111] Gao W, Li N et al. Ketohexokinase is involved in fructose utilization and promotes tumor progression in glioma. Biochem Biophys Res Commun. 2018 503:1298–306
[112] Li X, Qian X. et al. A splicing switch from ketohexokinase-C to ketohexokinase-A drives hepatocellular carcinoma formation. Nat Cell Biol. 2016 18:561–71
[113] Tee SS, Kim N et al. Ketohexokinase-mediated fructose metabolism is lost in hepatocellular carcinoma and can be leveraged for metabolic imaging. Sci Adv. 2022 8:eabm7985
[114] Ishimoto T, Lanaspa MA et al. Opposing effects of fructokinase C and A isoforms on fructose-induced metabolic syndrome in mice. Proc Natl Acad Sci. 2012 109:4320–5.
[115] Syamprasad NP, Jain S et al. AKR1B1 drives hyperglycemia-induced metabolic reprogramming in MASLD associated hepatocellular carcinoma. JHEP Rep. 2024 6:100974
[116] Zhou P, Chang WY et al. High dietary fructose promotes hepatocellular carcinoma progression by enhancing O GlcNAcylation via microbiota-derived acetate. Cell Metab. 2023 35:1961–75.e6
[117] Vásquez Martínez IP, Pérez-Campos E et al. O-GlcNAcylation: Crosstalk between Hemostasis, Inflammation, and Cancer. Int J Mol Sci. 2024 25:9896
[118] Huang X, Fang J et al. IL-6/STAT3 axis activates glut5 to regulate fructose metabolism and tumorigenesis. Int J Biol Sci. 2022 18:3668-75.
[119] Singh N, Baby D et al. Inflammation and cancer. Ann Afr Med. (2019) 18:121–6
[120] Fowle-Grider R, Rowles JL et al. Dietary fructose enhances tumour growth indirectly via interorgan lipid transfer. Nature. 2024 636:737-744
[121] Seyfried, T. N., Flores, R. E. et al. Cancer as a metabolic disease: implications for novel therapeutics. Carcinogenesis, 2014 35(3):515–527
[122] Pavlova N. N., Zhu J. et al. The hallmarks of cancer metabolism: Still emerging. Cell metabolism 2022 34(3):355–377
[123] Klement R. J., Pazienza, V. Impact of Different Types of Diet on Gut Microbiota Profiles and Cancer Prevention and Treatment. Medicina (Kaunas, Lithuania) 2019 55(4):84
[124] Zhu H., Bi D. et al. Ketogenic diet for human diseases: the underlying mechanisms and potential for clinical implementations. Signal transduction and targeted therapy 2022 7(1):11
[125] Ngo B., Van Riper J. M. et al. Targeting cancer vulnerabilities with high-dose vitamin C. Nature reviews. Cancer 2019 19(5):271–282.
[126] Ninomiya S., Nakamura N. et al. Low Levels of Serum Tryptophan Underlie Skeletal Muscle Atrophy. Nutrients 2020 12(4):978.

[127] Yadav M. K., Kumari I. et al.. Probiotics, prebiotics and synbiotics: Safe options for next-generation therapeutics. Applied microbiology and biotechnology, (2022)106(2), 505–521
[128] Homolak J., Babic Perhoc, A. et al. The Effect of Acute Oral Galactose Administration on the Redox System of the Rat Small Intestine. Antioxidants (Basel, Switzerland) 2021 11(1):37
[129] Homolak J., Babic Perhoc, A. et al. D-galactose might mediate some of the skeletal muscle hypertrophy-promoting effects of milk-A nutrient to consider for sarcopenia?. BioEssays : news and reviews in molecular, cellular and developmental biology 2024 46(2):e2300061
[130] Isenberg J., Stoffel B. et al. Liver lectin blocking with D-galactose to prevent hepatic metastases in colorectal carcinoma patients. Anticancer research 1997 17(5B):3767–3772
[131] Razaghi A., Poorebrahim M. et al. Selenium stimulates the antitumour immunity: Insights to future research. European journal of cancer (Oxford, England:1990) 2021 155:256–267
[132] Missiroli S., Perrone M. et al. Cancer metabolism and mitochondria: Finding novel mechanisms to fight tumours. EBioMedicine 2020 59:102943
[133] Beltrà M., Pöllänen N. et al. NAD+ repletion with niacin counteracts cancer cachexia. Nature communications 202314(1):1849
[134] Choi D. NADH-Reductive Stress in Cancer Cell Proliferation. Molecules and cells 2023 46(8):473–475
[135] Kraft M., Kraft K. et al. L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial. Nutrition journal 2012 11:52
[136] Xiong Y., Yong Z. et al. Hyperbaric Oxygen Activates Enzyme-Driven Cascade Reactions for Cooperative Cancer Therapy and Cancer Stem Cells elimination. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2023 10(21):e2301278
[137] Yanchu L, Rong P et al. Ozone therapy for high-grade glioma: an overview. Front Oncol. 2023 13:1161206
[138] Schönsteiner S. S., Bauder Mißbach H. A randomized exploratory phase 2 study in patients with chemotherapy-related peripheral neuropathy evaluating whole-body vibration training as adjunct to an integrated program including massage, passive mobilization and physical exercises. Experimental hematology & oncology 2017 6:5
[139] Huang Q., Wu M. et al. Muscle-to-tumor crosstalk: The effect of exercise-induced myokine on cancer progression. Biochimica et biophysica acta. Reviews on cancer 2022 1877(5):188761
[140] Roy P., Chowdhury S., Roy H. K. Exercise-induced myokines as emerging therapeutic agents in colorectal cancer prevention and treatment. Future oncology (London, England) 2018 14(4):309–312
[141] Poff A., Koutnik A. P., et al. Targeting the Warburg effect for cancer treatment: Ketogenic diets for management of glioma. Seminars in cancer biology 2019 56, 135–148
[142] Kraft M., Mosetter K. Melatonin, das Mikrobiom und die Ernährung – eine „Star Alliance"? OM & E 2024 189: F36-39
[143] Li Y., Li S. et al. Melatonin for the prevention and treatment of cancer. Oncotarget, 2017 8(24):39896–39921.
[144] Kraft M. Sekundäre Pflanzenstoffe in der Prävention von Krebserkrankungen - von der Zelle zum Organismus OM&E 2020, 173
[145] Kraft M. L-Carnitin – Therapeutische Optionen in der Medizin mit besonderem Fokus auf Tumorerkrankungen OM&E 2021 SH 120
[146] Kraft M., Pfeifer B. Metformin in der Krebstherapie. Der Onkologe, 2021 Forum Onkologie
[147] Kraft M. Stellenwert der hochdosierten intravenösen Vitamin-C-Gabe in der Tumortherapie. OM&E 2023, SH 130
[148] Kraft M., Mosetter K. Stellenwert von Cordycepin in der Tumortherapie und bei SARS-CoV-2. OM&E 2023, 184
[149] Kraft M., Pfeifer B. Indol-3-Carbinol – ein Blockbuster in der Prävention und Behandlung von Brustkrebs? Onkologe, 5/2023, 25-32
[150] Kraft M., Pfeifer B. Vertiefende Betrachtungen zur Entstehung, Ausbreitung und Metastasierung von Krebs. Onkologe, 5/2023, Suppl. 1
[151] Kraft M., Pfeifer B. Langzeitüberleben mit metastasiertem und kastrationsresistentem Prostatakarzinom. Onkologie heute 8/2023, 1-7
[152] Kraft M. Hyperthermie – was ist relevant bei der Tumortherapie? Gynäkologie & Geburtshilfe, 2023; 28(4), 48-50
[153] Kraft M., Mosetter K. Melatonin – nur ein Schlafhormon, oder doch mehr? OM&E 2024, 186
[154] Kraft M., Mosetter K., Pfeifer B. Melatonin in der Tumortherapie – eine Option? OM&E 2024, 187
[155] Kraft M. Artemisinin und dessen Derivate in der Krebstherapie: nur Ferroptose oder doch mehr? OM&E 2022, 181
[156] Kraft M. Veränderung der Tumormikroumgebung (TME) im Rahmen einer Hyperthermie. OM&E 2023, 183
[157] Bocci V. Mistletoe (viscum album) lectins as cytokine inducers and immunoadjuvant in tumor therapy. A review. Biol Regul Homeost Agents 1993 7(1):1
[158] Ganguly C., Das S. Plant lectins as inhibitors of tumos growth and modulations of host immune response. Chemotherapy 1994 40: 272-278
[159] Boneberg E. M., Hartung TMistletoe Lectin-1 Increases Tumor Necrosis Factor-α Release in Lipopolysaccharide-Stimulated Whole Blood via Inhibition of Interleukin-10 Production. Journal of Pharmacology and Experimental Therapeutics 2001 298(3): 996-999
[160] Beuth J, Stoffel B et al. Mistellektin-1 Neue therapeutische Perspektiven in der Onkologie. Onkologie 1995 18 (suppl 1):36-40
[161] Knezovic A., Osmanovic Barilar J. Glucagon-like peptide-1 mediates effects of oral galactose in streptozotocin-induced rat model of sporadic Alzheimer's disease. Neuropharmacology 2018 135:48-62

[162] Homolak J., Babic Perhoc A. Is Galactose a Hormetic Sugar? An Exploratory Study of the Rat Hippocampal Redox Regulatory Network. Molecular nutrition & food research, 2021 65(21):e2100400.
[163] Banik S. M., Pedram K. et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature, 2020 584(7820), 291–297.
[164] Skolik R. A., Solocinski, J. et al. Global changes to HepG2 cell metabolism in response to galactose treatment. American journal of physiology. Cell physiology, 2021 320(5): C778–C793.
[165] Sharif Swallah M., Bondzie-Quaye P. et al. Potentialities of Ganoderma lucidum extracts as functional ingredients in food formulation. Food research international (Ottawa, Ont.) 2023 172:113161.
[166] Zhang J., Tang Q. et al. Activation of B lymphocytes by GLIS, a bioactive proteoglycan from Ganoderma lucidum. Life sciences 2002 71(6):623–638.
[167] Swallah M. S., Bondzie-Quaye P. Therapeutic potential and nutritional significance of Ganoderma lucidum - a comprehensive review from 2010 to 2022. Food & function 2023 14(4):1812–1838.
[168] Batra P, Sharma AK et al. Probing Lingzhi or Reishi medicinal mushroom Ganoderma lucidum (higher Basidiomycetes): a bitter mushroom with amazing health benefits. Int J Med Mushrooms. 2013 15(2):127-43.
[169] Popović V, Živković J. et al. Mycotherapy of cancer: an update on cytotoxic and antitumor activities of mushrooms, bioactive principles and molecular mechanisms of their action. Curr Top Med Chem. 2013 13 (21):2791-806.
[170] Sun L. X., Li W. D. et al. Protection against lung cancer patient plasma-induced lymphocyte suppression by Ganoderma lucidum polysaccharides. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2014 33(2):289–299.
[171] Wu, G. S., Guo, J. J. et al. Anti-cancer properties of triterpenoids isolated from Ganoderma lucidum - a review. Expert opinion on investigational drugs, 2013 22(8): 981–992.
[172] Suarez-Arroyo I. J., Rosario-Acevedo R. et al. Anti-tumor effects of Ganoderma lucidum (reishi) in inflammatory breast cancer in in vivo and in vitro models. PloS one 2013 8(2):e57431.
[173] Loganathan J., Jiang, J. et al. The mushroom Ganoderma lucidum suppresses breast-to-lung cancer metastasis through the inhibition of pro-invasive genes. International journal of oncology 2014 44(6):2009–2015.
[174] Acevedo-Díaz A., Ortiz-Soto G. et al. Ganoderma lucidum Extract Reduces the Motility of Breast Cancer Cells Mediated by the RAC Lamellipodin Axis. Nutrients 2019 11(5): 1116.
[175] Swallah M. S., Bondzie-Quaye P. et al. Therapeutic potential and nutritional significance of Ganoderma lucidum - a comprehensive review from 2010 to 2022. Food & function 2023 14(4):1812–1838.
[176] Ratovitski E. A. Anticancer Natural Compounds as Epigenetic Modulators of Gene Expression. Current genomics 2017 18(2):175–205.
[177] Lai G., Guo Y. et al. Alcohol Extracts From Ganoderma lucidum Delay the Progress of Alzheimer's Disease by Regulating DNA Methylation in Rodents. Frontiers in pharmacology 2019 10:272.
[178] Seweryn E., Ziała, A. & Gamian A.. Health-Promoting of Polysaccharides Extracted from Ganoderma lucidum. Nutrients 2021 13(8):2725.
[179] Bouchardat, Apollinaire De la Glykosurie ou Diabète sucré. Paris 1875. Külz: Beitr. Diabetes, Marburg 1874
[180] Bouchardat Apollinaire (1883). de la Glycosurie Ou Diabète Sucré, Son Traitement Hygiénique, Avec Notes Et Documents: Sur La Nature Et Le Traitement de la Goutte
[181] Brünings W. Beiträge zum Krebsproblem. 1. Mitteilung: Über eine diätetisch-hormonale Beeinflussung des Krebses. Münchener Medizinische Wochenschrift 1941 88:117–23.
[182] Mohammad M. A., Sunehag A. L. et al. Galactose promotes fat mobilization in obese lactating and nonlactating women. The American journal of clinical nutrition, 2011 93(2), 374–381.
[183] Warburg O., Posener K., Negelein E. Über den Stoffwechsel der Carcinomzelle. Biochem Z. 1924 152:309-344
[184] Warburg O. On the Origin of Cancer Cells. Science 1956 123 (3191):309ff.
[185] Warburg O., Geissler A. W., & Lorenz S. Über Wachstum von Krebszellen in Medien, deren Glucose durch Galaktose ersetzt ist [On growth of cancer cells in media in which glucose is replaced by galactose]. Hoppe-Seyler's Zeitschrift fur physiologische Chemie 1967 348(12):1686–1687.
[186] Beuth J., Ko H.L. et al.: Inhibition of liver tumor cell colonization in two animal tumor modeis by lectin blocking with d-galactose or arabinogalactan. Clin Exp Metastasis 1988 6(2):115-120
[187] Isenberg J., Stoffel B. et al.: Liver lectin blocking with D-galactose to prevent hepatic metastases in colorectal carcinoma patients. Anticancer Res. 1997 17:3767-3772.
[188] Roseman J. M., Miller E. et al. The effect of L-fucose on rat mammary tumor growth. II. In vitro studies. J Surg Oncol 1971 3:79-88.
[189] Pulverer G., Ko H. L. et al. Combined immunmodulation (Propionibacterium avidum KP-40) and lectin blocking (D-galactose) prevents liver tumor colonization in BALB/c-mice. Int J Med Microbiol Virol Parasitol. Infect Dis 1994 281:491-494.
[190] Beuth J., Ko, H.L et al. Inhibition of liver metastasis in mice by blocking hepatocyte lectins with arabinogalactan infusions and D-galactose. J Cancer Res Clin Oncol. 1987 113(1):51-55
[191] Pulverer G, Ko H.L. et al. Blockade der Leberlektine durch Galaktoseinfusionen: therapeutisches Konzept zur Metastasenprophylaxe. Onkologie 1995 18(suppl 1):51-54

[192] Isenberg J., Stoffel B. et al. Liver lectin blocking with D-galactose to prevent hepatic metastases in colorectal carcinoma patients. Anticancer research 1997 17:3767–3772

[193] Warczynski P., Gil J. et al. Prevention of hepatic metastases by liver lectin blocking with D-galactose in colon cancer patients. A prospectively randomized clinical trial. Anticancer Res. 1997 17:1223-6.

[194] Kosik J., Gil J., et al. Prevention of hepatic metastases by liver lect in blocking with D-galactose in stomach cancer patients. A prospectively randomized clinical trial. Anticancer research 1997 17:1411–1415.

[195] Foell D, Kucharzik T, Kraft M et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 2003 52(6):847-53

[196] Stanczak M. A., Rodrigues Mantuano, N. et al. Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade. Science translational medicine 2022 14(669):eabj1270

[197] Conte F., van Buuringen N. et al. Galactose in human metabolism, glycosylation and congenital metabolic diseases: Time for a closer look. Biochimica et biophysica acta. General subjects 2021 1865(8):129898.

[198] Sosicka P., Ng B. G., & Freeze H. H. Therapeutic Monosaccharides: Looking Back, Moving Forward. Biochemistry 2020 59(34):3064–3077.

[199] Park J. H. 2023 SLC39A8-CDG. In M. P. Adam (Eds.) et. al., GeneReviews®. University of Washington, Seattle.

[200] Homolak J., Babic Perhoc A. et al. D-galactose might protect against ionizing radiation by stimulating oxidative metabolism and modulating redox homeostasis. Journal of radiation research, 2023 64(4):743–745.

[201] Zhu T., Wang Z. et al. D-galactose protects the intestine from ionizing radiation-induced injury by altering the gut microbiome. Journal of radiation research 2022 63(6):805–816.

[202] Klein A, Wrulich OA, Uberall F. Pathway-focused bioassays and transcriptome analysis contribute to a better activity monitoring of complex herbal remedies. BMC Genomics. 2013 14:133

[203] Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 100(1):57-70

[204] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011 144(5):646-74

[205] Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020 30(16):R921-R925

[206] Jenny M, Schwaiger W, Ueberall F. Apoptosis induced by the Tibetan herbal remedy PADMA 28 in the T cell-derived lymphocytic leukaemia cell line CEM-C7H2. J Carcinog. 2005 4:15

[207] Wang R, Wang C et al. Baicalin and baicalein in modulating tumor microenvironment for cancer treatment: A comprehensive review with future perspectives. Pharmacol Res. 2024 199:107032

[208] Wu H, Long X et al. Combined use of phospholipid complexes and self-emulsifying microemulsions for improving the oral absorption of a BCS class IV compound, baicalin. Acta Pharm Sin B. 2014 4(3):217-26

[209] Akao T, Kawabata K, et al. Baicalin, the predominant flavone glucuronide of scutellariae radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to its original form. J Pharm Pharmacol. 2000 52(12):1563-8

[210] Rahmani AH, Almatroudi A et al. The Multifaceted Role of Baicalein in Cancer Management through Modulation of Cell Signalling Pathways. Molecules 2022 27(22):8023

[211] Kim D.H., Hossain M.A. et al. Baicalein, an active component of Scutellaria baicalensis Georgi, induces apoptosis in human colon cancer cells and prevents AOM/DSS-induced colon cancer in mice. Int. J. Oncol. 2013 43:1652–1658

[212] Takahashi H, Chen MC et al. Baicalein, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells. Biochim Biophys Acta. 2011 1813(8):1465-74

[213] Chen F, Zhuang M et al. Baicalein inhibits migration and invasion of gastric cancer cells through suppression of the TGF-β signaling pathway. Mol Med Rep. 2014 10(4):1999-2003.

[214] Liu J, Qi X et al. Baicalin Induces Gastric Cancer Cell Pyroptosis through the NF-κB-NLRP3 Signaling Axis. J Cancer. 2024 15(2):494-507

[215] Zhu Y, Fang J. et al. Baicalin suppresses proliferation, migration, and invasion in human glioblastoma cells via Ca2+-dependent pathway. Drug Des Devel Ther. 2018 12:3247-3261

[216] Choi EO, Cho EJ et al. Baicalein Inhibits the Migration and Invasion of B16F10 Mouse Melanoma Cells through Inactivation of the PI3K/Akt Signaling Pathway. Biomol Ther (Seoul). 2017 25(2):213-221

[217] Susmitha GD, Miyazato K et al. Anti-metastatic Effects of Baicalein by Targeting STAT3 Activity in Breast Cancer Cells. Biol Pharm Bull. 2020 43(12):1899-1905

[218] Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017 17(9):559-572.

[219] de Visser KE, Joyce JA. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 2023 41(3):374-403

[220] Kitamura T, Qian BZ, Pollard JW. Immune cell promotion of metastasis. Nat Rev Immunol. 2015 15(2):73-86

[221] Qian BZ. Inflammation fires up cancer metastasis. Semin Cancer Biol. 2017 Dec;47:170-176

[222] Ke M, Zhang Z, Xu B, Zhao S, Ding Y, Wu X, Wu R, Lv Y, Dong J. Baicalein and baicalin promote antitumor immunity by suppressing PD-L1 expression in hepatocellular carcinoma cells. Int Immunopharmacol. 2019 Oct;75:105824

[223] Schroecksnadel S, Jenny M, Kurz K, Klein A, Ledochowski M, Uberall F, Fuchs D. LPS-induced NF-kappaB expression in THP-1Blue cells correlates with neopterin production and activity of indoleamine 2,3-dioxygenase. Biochem Biophys Res Commun. 2010 Sep 3;399(4):642-6

[224] Prendergast GC. Cancer: Why tumours eat tryptophan. Nature. 2011 478(7368):192-4
[225] Opitz CA, Litzenburger UM et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature. 2011 478(7368):197-203
[226] Chen S, Corteling R et al. Natural inhibitors of indoleamine 3,5-dioxygenase induced by interferon-gamma in human neural stem cells. Biochem Biophys Res Commun. 2012 429(1-2):117-23
[227] Becker K, Geisler S, Ueberall F et al. Immunomodulatory properties of cacao extracts - potential consequences for medical applications. Front Pharmacol. 2013 4:154
[228] Gostner JM, Becker K, Ueberall F, Fuchs D. The good and bad of antioxidant foods: An immunological perspective. Food Chem Toxicol. 2015 80:72-79
[229] Saleem A, Husheem M et al. Inhibition of cancer cell growth by crude extract and the phenolics of Terminalia chebula retz. fruit. J Ethnopharmacol. 2002 81(3):327-36
[230] Jenny M, Schwaiger W, Ueberall F. Apoptosis induced by the Tibetan herbal remedy PADMA 28 in the T cell-derived lymphocytic leukaemia cell line CEM-C7H2. J Carcinog. 2005 4:15
[231] Saller R, Melzer J. Multimorbidität und multi-target-therapie in der phytotherapie [Multimorbidity and multi-target therapy in phytotherapy]. Forsch Komplementmed. 2013 20 Suppl 2:1. German
[232] Peterson CT, Denniston K, Chopra D. Therapeutic Uses of Triphala in Ayurvedic Medicine. J Altern Complement Med. 2017 23(8):607-614
[233] Prasad S, Srivastava SK. Oxidative Stress and Cancer: Chemopreventive and Therapeutic Role of Triphala. Antioxidants (Basel). 2020 9(1):72
[234] Reddy P, Pradeep S et al. Cell cycle arrest and apoptotic studies of Terminalia chebula against MCF-7 breast cancer cell line: an in vitro and in silico approach. Front Oncol. 2023 13:1221275
[235] Hu S, Li S et al. The antitumor effects of herbal medicine Triphala on oral cancer by inactivating PI3K/Akt signaling pathway: based on the network pharmacology, molecular docking, in vitro and in vivo experimental validation. Phytomedicine. 2024 128:155488
[236] Lu G, Wang X et al. The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art. Biomed Pharmacother. 2023 165:115132.
[237] Kumar G, Madka V et al. Molecular Mechanisms of Cancer Prevention by Gooseberry (Phyllanthus emblica). Nutr Cancer. 2022 74(7):2291-2302
[238] Singai C, Pitchakarn P et al. Chemopreventive Potential of Phyllanthus emblica Fruit Extract against Colon and Liver Cancer Using a Dual-Organ Rat Carcinogenesis Model. Pharmaceuticals (Basel). 2024 17(7):818
[239] Baliga MS, Dsouza JJ. Amla (Emblica officinalis Gaertn), a wonder berry in the treatment and prevention of cancer. Eur J Cancer Prev. 2011 20(3):225-39
[240] Chang Z, Jian P et al. Tannins in Terminalia bellirica inhibit hepatocellular carcinoma growth by regulating EGFR-signaling and tumor immunity. Food Funct. 2021 12(8):3720-3739
[241] Sales MS, Roy A et al. Octyl gallate and gallic acid isolated from Terminalia bellarica regulates normal cell cycle in human breast cancer cell lines. Biomed Pharmacother. 2018 103:1577-1584
[242] Patra S, Panda PK et al. Terminalia bellirica extract induces anticancer activity through modulation of apoptosis and autophagy in oral squamous cell carcinoma. Food Chem Toxicol. 2020 136:111073
[243] Jiang J, Yang Z et al. The potential mechanism of Chebulae Fructus in the treatment of hepatocellular carcinoma on the basis of network pharmacology. Ann Hepatol. 2022 27(4):100701
[244] Kuo YC, Kuo PL et al. Ellipticine induces apoptosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells. Life Sci. 2006 78(22):2550-7.
[245] Kuo PL, Hsu YL et al. The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. Cancer Lett. 2005 223(2):293-301.
[246] Vadde R, Radhakrishnan S et al. Triphala Extract Suppresses Proliferation and Induces Apoptosis in Human Colon Cancer Stem Cells via Suppressing c-Myc/Cyclin D1 and Elevation of Bax/Bcl-2 Ratio. Biomed Res Int. 2015 2015:649263.
[247] Russell LH Jr, Mazzio E et al. Differential cytotoxicity of triphala and its phenolic constituent gallic acid on human prostate cancer LNCap and normal cells. Anticancer Res. 2011 31(11):3739-45.
[248] Sandhya T, Mishra KP. Cytotoxic response of breast cancer cell lines, MCF 7 and T 47 D to triphala and its modification by antioxidants. Cancer Lett. 2006 18;238(2):304-13
[249] Zhang Z, Huang L et al. Annexin 1 induced by anti-inflammatory drugs binds to NF-kappaB and inhibits its activation: anticancer effects in vitro and in vivo. Cancer Res. 2010 70(6):2379-88
[250] Zhao Y, Wang M et al. An Integrated Study on the Antitumor Effect and Mechanism of Triphala Against Gynecological Cancers Based on Network Pharmacological Prediction and In Vitro Experimental Validation. Integr Cancer Ther. 2018 17(3):894-901
[251] Tsering J, Hu X. Triphala Suppresses Growth and Migration of Human Gastric Carcinoma Cells In Vitro and in a Zebrafish Xenograft Model. Biomed Res Int. 2018 2018:7046927
[252] Cheriyamundath S, Mahaddalkar T et al. Aqueous extract of Triphala inhibits cancer cell proliferation through perturbation of microtubule assembly dynamics. Biomed Pharmacother. 2018 98:76-81
[253] Shi Y, Sahu RP et al. Triphala inhibits both in vitro and in vivo xenograft growth of pancreatic tumor cells by inducing apoptosis. BMC Cancer. 2008 Oct 10;8:294
[254] Gurjar S, Pal A, Kapur S. Triphala and its constituents ameliorate visceral adiposity from a high-fat diet in mice with diet-induced obesity. Altern Ther Health Med. 2012 Nov-Dec;18(6):38-45. PMID: 23251942.

[255] Kalaiselvan S, Rasool M. Triphala exhibits anti-arthritic effect by ameliorating bone and cartilage degradation in adjuvant-induced arthritic rats. Immunol Invest. 2015 44(4):411-26
[256] Čižmáriková M, Michalková R et al. Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence. Biomolecules. 2023 13(11):1653
[257] Wang M, Li Y et al. Chebulinic acid derived from triphala is a promising antitumour agent in human colorectal carcinoma cell lines. BMC Complement Altern Med. 2018 [18(1):342
[258] Ghadimi M, Foroughi F et al. Decreased insulin resistance in diabetic patients by influencing Sirtuin1 and Fetuin-A following supplementation with ellagic acid: a randomized controlled trial. Diabetol Metab Syndr. 2021 13(1):16
[259] Mirzaie Z, Bastani A et al. Effects of Ellagic Acid on Oxidative Stress Index, Inflammatory Markers and Quality of Life in Patients With Irritable Bowel Syndrome: Randomized Double-blind Clinical Trial. Clin Nutr Res. 2022 11(2):98-109
[260] Dhingra D, Chhillar R. Antidepressant-like activity of ellagic acid in unstressed and acute immobilization-induced stressed mice. Pharmacol Rep. 2012 64(4):796-807
[261] Liu Y, Yu S et al. Chronic administration of ellagic acid improved the cognition in middle-aged overweight men. Appl Physiol Nutr Metab. 2018 43(3):266-273
[262] Mohanty S, Gupta AC et al. Ameliorative Effects of Dietary Ellagic Acid Against Severe Malaria Pathogenesis by Reducing Cytokine Storms and Oxidative Stress. Front Pharmacol. 2021 12:777400
[263] Widner B, Ledochowski M, Fuchs D. Interferon-gamma-induced tryptophan degradation: neuropsychiatric and immunological consequences. Curr Drug Metab. 2000 1(2):193-204
[264] Schröcksnadel K, Wirleitner B et al. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta. 2006 364(1-2):82-90
[265] Gostner JM, Becker K et al. Disturbed Amino Acid Metabolism in HIV: Association with Neuropsychiatric Symptoms. Front Psychiatry. 2015 6:97
[266] Gargaro M, Scalisi G et al. Indoleamine 2,3-dioxygenase 1 activation in mature cDC1 promotes tolerogenic education of inflammatory cDC2 via metabolic communication. Immunity. 2022 55(6):1032-1050.e14
[267] Hajiluian G, Karegar SJ et al. The effects of Ellagic acid supplementation on neurotrophic, inflammation, and oxidative stress factors, and indoleamine 2,3-dioxygenase gene expression in multiple sclerosis patients with mild to moderate depressive symptoms: A randomized, triple-blind, placebo-controlled trial. Phytomedicine. 2023 121:155094.
[268] Oana Zanoaga et al. Implications of dietary ω-3 and ω-6 polyunsaturated fatty acids in breast cancer (Review). Experimental and therapeutic medicine 2018 15:1167-1176
[269] Philippe Bougnoux et al., Fatty acids and breast cancer: sensitization to treatments and prevention of metastatic re-growth, Prog Lipid Res. 2010 49(1):76-86
[270] Simopoulos AP. Essential fatty acids in health and chronic disease. Am J Clin Nutr. 1999 70(3 Suppl):560S-569S
[271] Uwe Gröber, Orthomolekulare Medizin – Ein Leitfaden für Apotheker und Ärzte, 4. Auflage. 2021, Wissenschaftliche Verlagsgesellschaft Stuttgart (WVG , ISBN 978-3-8047-2271-2
[272] Chavarro JE, Stampfer MJ et al. A prospective Study of polyunsaturated fatty acid levels in blood and prostate cancer. Cancer Epidemiol Biomarkers Prev 2012 21(2):319-26
[273] Jing K, Song KS. et al. Docosahexaenoic acid induces autophagy through p53/AMPK/mTOR signaling and promotes apoptosis in human cancer cells harboring wild-type p53. Autophagy 2011; 7:11,1348-1358
[274] Yang B, Ren XL et al. Ratio of n-3/n-6 PUFAs and risk of breast cancer: a meta-analysis of 274135 adult females from 11 independent prospective studies, BMC Cancer. 2014 14:105
[275] Kang JX, Liu A. The role of the tissue omega-6/omega-3 fatty acid ratio in regulating tumor angiogenesis Cancer Metastasis Rev. 2013 32(1-2):201-10
[276] Gago-Dominguez M, Yuan JM et al., Opposing effects of dietary n-3 and n-6 fatty acids on mammary carcinogenesis: The Singapore Chinese Health Study, Br J Cancer. 2003 89(9):1686-92
[277] Aglago EK, Huybrechts I. et al. Consumption of Fish and Long-chain n-3 Polyunsaturated Fatty Acids Is Associated With Reduced Risk of Colorectal Cancer in a Large European Cohort. Clin Gastroenterol Hepatol. 2020 18(3):654-666.e6
[278] Chajès V, Torres-Mejía G et al. ω-3 and ω-6 Polyunsaturated fatty acid intakes and the risk of breast cancer in Mexican women: impact of obesity status. Cancer Epidemiol Biomarkers Prev. 2012 21(2):319-26
[279] Terry PD, Rohan TE, Wolk A. Intakes of fish and marine fatty acids and the risks of cancers of the breast and prostate and of other hormone-related cancers: a review of the epidemiologic evidence, Am J Clin Nutr. 2003 77(3):532-43
[280] Newell M, Mazurak V. et al., N-3 Long-Chain Polyunsaturated Fatty Acids, Eicosapentaenoic and Docosahexaenoic Acid, and the Role of Supplementation during Cancer Treatment: A Scoping Review of Current Clinical Evidence, Cancers (Basel). 2021 13(6):1206
[281] Hatfield DL, Berry MJ, Gladyshev VN, editors. Selenium: Its Molecular Biology and Role in Human Health. Springer Science+Business Media, LLC; 2012.
[282] Schwarz K, Foltz CM. Faktor-3-Aktivität von Selenverbindungen. J. Biol. Chem. 1958;233:245–251
[283] Zhang Y, Gladyshev VN. Comparative genomics of trace element dependence in biology. J. Biol. Chem. 2011;286:23623–23629. doi: 10.1074/jbc.R110.172833
[284] Gerrad D Jones, Boris Droz, Peter Greve, Pia Gottschalk, Deyan Poffetd, Steve P McGrath, Sonia I Seneviratne, Pete Smith, Lenny H E Winkel: Selenium deficiency risk predicted to increase under future climate change, 2017 Feb 21;114(11):2848–2853. doi: 10.1073/pnas.1611576114, Proc Natl Acad Sci USA

[285] Winkel LHE, et al. Selenium cycling across soil-plant-atmosphere interfaces: A critical review. Nutrients. 2015;7(6):4199–4239. doi: 10.3390/nu7064199
[286] Hatfield DL, Tsuji PA, Carlson BA, Gladyshev VN Selen und Selenocystein: Rollen bei Krebs, Gesundheit und Entwicklung. Trends Biochem. Sci. 2014;39:112–120. doi: 10.1016/j.tibs.2013.12.007.
[287] Flohé L, Brigelius-Flohé R. Selenoproteins of the glutathione peroxidase family. In: Hatfield DL, Berry MJ, Gladyshev VN, editors. Selenium: Its molecular biology and role in human health. 3rd edn. Springer Science+Business Media, LLC; 2012. pp. 167–180.
[288] Banning A, et al. Glutathione peroxidase 2 and its role in cancer. In: Hatfield DL, Berry MJ, Gladyshev VN, editors. Selenium: Its molecular biology and role in human health. 3rd edn. Springer Science+Business Media, LLC; 2012. pp. 271–282
[289] Brigelius-Flohe R, et al. The yin and yang of nrf2-regulated selenoproteins in carcinogenesis. Int. J. Cell Biol. 2012;2012:486147. doi: 10.1155/2012/486147
[290] Dewa Y, et al. Molecular expression analysis of beta-naphthoflavone-induced hepatocellular tumors in rats. Toxicol. Pathol. 2009;37(4):446–455. doi: 10.1177/0192623309335063
[291] Kamil Demircan, Ylva Bengtsson, Thilo Samson Chillon, Johan Vallon-Christersson, Qian Sun, Christer Larsson, Martin Malmberg, Lao H Saal, Lisa Rydén, Åke Borg, Jonas Manjer, Lutz Schomburg: Matched analysis of circulating selenium with the breast cancer selenotranscriptome: a multicentre prospective study; J Transl Med. 2023 Sep 23;21:658. doi: 10.1186/s12967-023-04502-y
[292] Demircan K, Bengtsson Y, Sun Q, Brange A, Vallon-Christersson J, Rijntjes E, et al. Serumselen, Selenoprotein P und Glutathionperoxidase 3 als Prädiktoren für Mortalität und Rezidiv nach Brustkrebsdiagnose: eine multizentrische Kohortenstudie. Redox Biol. 2021;47:102145. doi: 10.1016/j.redox.2021.102145.
[293] Hoffmann PR, Höge SC, Li PA, Hoffmann FW, Hashimoto AC, Berry MJ. The selenoproteome exhibits widely varying, tissue-specific dependence on selenoprotein P for selenium supply. Nucleic Acids Res. 2007;35(12):3963–3973. doi: 10.1093/nar/gkm355
[294] Demircan K, Sun Q, Bengtsson Y, Seemann P, Vallon-Christersson J, Malmberg M, et al. Autoimmunity to selenoprotein P predicts breast cancer recurrence. Redox Biol. 2022;53:102346. doi: 10.1016/j.redox.2022.102346
[295] Kamil Demircan, Ylva Bengtsson, Qian Sun, Annie Brange, Johan Vallon-Christersson, Eddy Rijntjes, Martin Malmberg, Lao H Saal, Lisa Rydén, Åke Borg, Jonas Manjer, Lutz Schomburg: Serum selenium, selenoprotein P and glutathione peroxidase 3 as predictors of mortality and recurrence following breast cancer diagnosis: A multicentre cohort study; Redox Biol. 2021 Sep 21;47:102145. doi: 10.1016/j.redox.2021.102145
[296] Ralph Muecke, M.D., Lutz Schomburg, Ph.D.†, Michael Glatzel, M.D., Norman Willich, M.D., Oliver Micke, M.D.: CLINICAL INVESTIGATIONVolume 78, Issue 3P828-835November 01, 2010; Download Full IssueMulticenter, Phase 3 Trial Comparing Selenium Supplementation With Observation in Gynecologic Radiation Oncology
[297] Susan J Knox, Priya Jayachandran, Christine A Keeling †, Kathryn J Stevens †, Navjot Sandhu, Stacy Leanne Stamps-DeAnda, Rada Savic §, Lei Shura, Mark K Buyyounouski, Kevin Grimes: Results from a Phase 1 Study of Sodium Selenite in Combination with Palliative Radiation Therapy in Patients with Metastatic Cancer; Transl Oncol. 2019 Aug 24;12(11):1525–1531. doi: 10.1016/j.tranon.2019.08.006